Annual Report 2009 - Daiichi Sankyo

More documents

Recommendations

Info

PROFILE Daiichi Sankyo Co., Ltd., was established in 2005, after the merger of two leading centuryold Japanese pharmaceutical companies. With more than 100 years of scientific expertise across a wide range of therapeutic categories, our new Company draws upon a rich legacy of innovation and a robust pipeline of promising new compounds. Our corporate mission is “to contribute to the enrichment of quality of life around the world through the creation and provision of innovative pharmaceuticals.” To fulfill this mission, we are striving to realize our vision for 2015, to become a “Global Pharma Innovator,” and are making unceasing efforts to increase our corporate value, which we view as the sum of our social value, economic value, and humanistic value. OUR VISION FOR 2015 Global Pharma Innovator Global Extending our global reach Pharma Fulfilling unmet medical needs Innovator Innovations in science, technology, and business model
Three Years Young— See How Much We’ve Achieved! Global Market DAIICHI SANKYO TODAY* Annual Net Sales of ¥842.1 Billion 7 emerging countries (Brazil, Russia, India, China, South Korea, Turkey, Mexico) 91.1 No. 3 in Japan and No. 22 in the World Annual Overseas Sales of ¥373.3 Billion 44.3% of Our Sales Strong Growth in Olmesartan (Billions of yen) 250 200 Other 160.6 Japan 77.0 2008 Pharmaceutical Market US$773.1 billion Top 5 Europe (France, Germany, Italy, U.K., Spain) 153.4 189.2 211.1 U.S.A. 291.0 Copyright 2009 IMS Health. All rights reserved. Source: IMS World Review 2009. Reprinted with permission. Annual R&D of ¥184.5 Billion 150 100 144.7 21.9% of Annual Net Sales Return to Shareholders ¥102 Billion in Total Return * Figures are actual figures recorded for fiscal 2008. 50 0 FY2006 FY2007 FY2008 U.S.A. Japan EU Other Note: Excluding the impact of fiscal period adjustments Total Return to Shareholders (Billions of yen) 120 102.0 90 83.6 56.3 60 50.3 43.7 30 43.7 45.7 33.3 0 FY2006 FY2007 FY2008 Dividends Share buybacks CONTENTS 01 Daiichi Sankyo Today 04 Consolidated Financial Highlights 05 To Our Stakeholders 06 Message from the President 09 Special Features: Strategic Moves 10 Expanding Our Business 12 Groundbreaking Debut of Prasugrel 14 Realizing the Hybrid Business Model 18 R&D 24 Sales and Marketing Operations 31 Glossary of Terms 32 Corporate Governance and Internal Control System 36 Corporate Social Responsibility (CSR) 38 Financial Section 77 Corporate Information Forward-Looking Statements This annual report contains forward-looking statements regarding the Company’s plans, outlook, strategies, and results for the future. All forward-looking statements are based on judgements derived from the information available to the Company at the time of publication. Certain risks and uncertainties could cause the Company’s actual results to differ from any projections presented in this report. These risks and uncertainties include, but are not limited to, the economic circumstances surrounding the Company’s business; competitive pressures; related laws and regulations; product development programs; and foreign currency fluctuations. Daiichi Sankyo Co., Ltd. Annual Report 2009 01
Page 1: DAIICHI SANKYO CO., LTD. Annual Rep
Page 5 and 6: CONSOLIDATED FINANCIAL HIGHLIGHTS D
Page 7 and 8: MESSAGE FROM THE PRESIDENT “We ar
Page 9 and 10: Our third challenge is to make stea
Page 11 and 12: STRATEGIC MOVE 1: EXPANDING OUR BUS
Page 13 and 14: STRATEGIC MOVE 2: GROUNDBREAKING DE
Page 15 and 16: STRATEGIC MOVE 3: REALIZING THE HYB
Page 17 and 18: The hybrid business model offers at
Page 19 and 20: R&D The launch of Effient/Efient of
Page 21 and 22: Enriching the Oncology Pipeline In
Page 23 and 24: Development Pipeline Development Co
Page 25 and 26: SALES AND MARKETING OPERATIONS Pres
Page 27 and 28: United States DAIICHI SANKYO, INC.
Page 29 and 30: Europe DAIICHI SANKYO EUROPE GmbH (
Page 31 and 32: Healthcare Business Striving to Rea
Page 33 and 34: CORPORATE GOVERNANCE AND INTERNAL C
Page 35 and 36: Board of Directors (As of June 26,
Page 37 and 38: CORPORATE SOCIAL RESPONSIBILITY (CS
Page 39 and 40: FINANCIAL SECTION Consolidated Fina
Page 41 and 42: ■ Japan Fiscal 2008 net sales in
Page 43 and 44: Financial Position At March 31, 200
Page 45 and 46: Consolidated Balance Sheets DAIICHI
Page 47 and 48: Consolidated Statements of Operatio
Page 49 and 50: Consolidated Statements of Cash Flo
Page 51 and 52: Held-to-maturity debt securities ar
Page 53 and 54:
Accounting for Certain Lease Transa
Page 55 and 56:
In the year ended March 31, 2007, t
Page 57 and 58:
(2) At March 31, 2009 and 2008, car
Page 59 and 60:
Future lease payments at March 31,
Page 61 and 62:
Net deferred tax assets as of March
Page 63 and 64:
11. Retirement and Termination Bene
Page 65 and 66:
(a) 2) Purpose of acquisition To de
Page 67 and 68:
15. Segment Information (1) Busines
Page 69 and 70:
As described in note 2 to the conso
Page 71 and 72:
17. Stock Option Plans The Company
Page 73 and 74:
Individuals covered by the plan: 20
Page 75 and 76:
Price information of stock options
Page 77 and 78:
Independent Auditors’ Report 76 D
Page 79 and 80:
(As of June 2009) Paid-in Equity Ow
Page 81:
3-5-1, Nihonbashi Honcho, Chuo-ku,
show all

Annual Report 2009 - Daiichi Sankyo

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?